Theravance Biopharma, Inc. (TBPH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 26,195 | 15,388 | 16,868 | 14,256 |
| Impairment of long-lived assets to be disposed of | - | - | 1,562 | 2,951 |
| Selling, general and administrative | 18,430 | 18,370 | 16,875 | 17,056 |
| Research and development | 10,490 | 11,452 | 9,268 | 9,954 |
| Total expenses | 28,920 | 29,822 | 27,705 | 29,961 |
| Loss from operations | -2,725 | -14,434 | -10,837 | -15,705 |
| Interest expense (non-cash) | 663 | 643 | 630 | 644 |
| Net gain on realized contingent milestone and royalty assets | 75,137 | - | - | - |
| Interest and other income, net | 1,457 | 939 | 1,415 | 1,128 |
| Income (loss) before income taxes | 73,206 | -14,138 | -10,052 | -15,221 |
| Provision for income tax expense | 18,371 | -559 | 2,646 | 1,308 |
| Net income (loss) | 54,835 | -13,579 | -12,698 | -16,529 |
| Net unrealized gain (loss) on available-for-sale investments | -10 | -7 | 72 | 19 |
| Total comprehensive income (loss) | 54,825 | -13,586 | -12,626 | -16,510 |
| Earnings per share, basic | 1.09 | -0.27 | -0.26 | -0.34 |
| Earnings per share, diluted | 1.08 | -0.27 | -0.26 | -0.34 |
| Weighted average number of shares outstanding, basic | 50,177,000 | 49,706,000 | 49,038,000 | 48,747,000 |
| Weighted average number of shares outstanding, diluted | 50,726,000 | 49,706,000 | 49,038,000 | 48,747,000 |